On June 11, 2026, Ascentage Pharma Group International announced that the trustee for the company's 2022 Restricted Share Unit (RSU) Scheme has purchased shares. The company operates in the biotechnology industry and develops innovative small-molecule targeted therapies for cancer and autoimmune diseases.
